| Name | Title | Contact Details |
|---|
Metabiota is the pioneer in comprehensive risk analytics that improve the world`s resilience to epidemics. Built on a strong foundation of epidemiology and international field science, including a worldwide network of on-the-ground experts, Metabiota delivers actionable, data-driven insights that help countries, governments and corporations manage and mitigate infectious diseases. With a strategic global presence and sustained partnerships, Metabiota`s agile approach is helping the world track and transfer the risk associated with epidemic threats.
Marine Desalination Systems, L.L is a Saint Petersburg, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Actuate Therapeutics, Inc. is a private biopharmaceutical company focused on the development of compounds for use in the treatment of cancer, and inflammatory diseases leading to fibrosis and neurodegeneration.
REGENXBIO is a leading biotechnology company focused on the development, commercialization and licensing of recombinant adeno‐associated virus (AAV) gene therapy. REGENXBIO`s NAV® Technology Platform, a proprietary AAV gene delivery platform, consists of exclusive rights to more than 100 novel AAV vectors, including AAV7, AAV8, AAV9 and AAVrh10. REGENXBIO`s mission is to transform the lives of patients suffering from severe diseases with significant unmet medical need by developing and commercializing in vivo gene therapy products based on REGENXBIO`s NAV Technology Platform. REGENXBIO seeks to accomplish this mission through a combination of internal development efforts and third‐party NAV Technology Platform licensees.
Autobahn Therapeutics is focused on improving life health for people affected by CNS disorders by driving the regenerative power of the human body. Altering the progressive and debilitating course of these conditions by returning the brain to a healthier state will transcend the benefits offered by existing therapies and allow people to live the futures they deserve.